Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was USD 30.56 million compared to USD 29.8 million a year ago. Net loss was USD 8.02 million compared to net income of USD 0.772 million a year ago. Basic loss per share from continuing operations was USD 14.4 compared to basic earnings per share from continuing operations of USD 1.8 a year ago. Diluted loss per share from continuing operations was USD 14.4 compared to diluted earnings per share from continuing operations of USD 1.8 a year ago.